Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey.
Hum Reprod. 2012 Jun;27(6):1840-5. doi: 10.1093/humrep/des113. Epub 2012 Apr 3.
We aimed to determine the impact of an oral contraceptive (OC) treatment on health-related quality of life (HRQOL), depressive and anxiety symptoms in polycystic ovary syndrome (PCOS).
OC therapy in PCOS improves hirsutism and menstrual disturbances, along with HRQOL. This improvement is not associated with any change in the prevalence of depressive and anxiety symptoms. WHAT IS KNOWN AND WHAT THIS ARTICLE ADDS: Limited data are available regarding the effects of an OC on HRQOL, and depressive and anxiety symptoms in PCOS. This study reports the effects of the ethinyl estradiol/drospirenone (EE/DRSP) OC on an HRQOL questionnaire for women with PCOS (PCOSQ), depressive and anxiety symptoms after 6 months of treatment.
Prospective observational study. All participants completed PCOSQ, Beck Depression Inventory, Hospital Anxiety and Depression Scale and General Health Questionnaire. Serum androgens, fasting insulin, fasting and postload glucose values during an oral glucose tolerance test were measured. Changes in these variables and the scores of questionnaires were evaluated after 6 months of treatment with EE/DRSP (3 mg/30 μg).
Thirty-six patients with PCOS without a previous psychiatric diagnosis were included in the study.
The main complaints of the patients were hirsutism and irregular menses. Accordingly, menstrual and hirsutism problems were the most serious concerns followed by emotional problems on the PCOSQ. Eight patients (22.2%) had clinical depression scores. After treatment, regular menstrual cycles were attained and hirsutism was significantly improved in all patients. Hirsutism and emotion domains of the PCOSQ improved at 6 months (P< 0.05 for both). Depression was improved in five of eight depressive patients and four new patients showed increased depression scores. Overall, depression, anxiety mean scores and depression rates did not show a significant change.
BIAS, CONFOUNDING AND OTHER REASONS FOR CAUTION: The study is subject to the strengths and limitations of observational study design. A limitation of our study is the small sample size and lack of data related to possible confounding factors.
Generalizable to Caucasian PCOS.
我们旨在确定口服避孕药(OC)治疗对多囊卵巢综合征(PCOS)患者健康相关生活质量(HRQOL)、抑郁和焦虑症状的影响。
OC 治疗可改善 PCOS 患者的多毛症和月经紊乱,并改善 HRQOL。这种改善与抑郁和焦虑症状的患病率变化无关。
关于 OC 对 PCOS 患者 HRQOL 和抑郁、焦虑症状的影响,相关数据有限。本研究报告了屈螺酮炔雌醇(EE/DRSP)OC 对 PCOS 女性 HRQOL 问卷(PCOSQ)、治疗 6 个月后抑郁和焦虑症状的影响。
前瞻性观察研究。所有参与者均完成 PCOSQ、贝克抑郁量表、医院焦虑和抑郁量表和一般健康问卷。测量口服葡萄糖耐量试验期间的血清雄激素、空腹胰岛素、空腹和负荷后血糖值。治疗 6 个月后,评估这些变量和问卷评分的变化,采用 EE/DRSP(3 毫克/30 微克)治疗。
36 名无先前精神科诊断的 PCOS 患者纳入研究。
患者的主要主诉是多毛症和月经不规律。因此,PCOSQ 中月经和多毛症问题是最严重的问题,其次是情绪问题。8 名患者(22.2%)有临床抑郁评分。治疗后,所有患者均获得规律的月经周期,多毛症显著改善。PCOSQ 的多毛症和情绪领域在 6 个月时得到改善(两者均 P<0.05)。8 名抑郁患者中有 5 名抑郁症状改善,4 名新患者抑郁评分增加。总体而言,抑郁、焦虑平均评分和抑郁发生率没有明显变化。
偏倚、混杂因素和其他注意事项:该研究受观察性研究设计的优势和局限性的影响。本研究的一个局限性是样本量小,缺乏可能的混杂因素相关数据。
可推广至白种人 PCOS。